Information Provided By: 
Fly News Breaks for July 25, 2017
LLY
Jul 25, 2017 | 12:26 EDT
Cowen analyst Steve Scala said that Eli Lilly's Q2 revenue and EPS beat was driven by "solid sales" across most of its key products and he raised his 2017 estimate by a nickel to $4.15 after the company raised its own forecasts for 2017 earnings and sales. However, he called the delay in the resubmission of the NDA for baricitinib for RA a "disappointment" and "a cloud" amid the earnings report. Scala has an Outperform rating and $95 price target on Lilly shares.
News For LLY From the Last 2 Days
There are no results for your query LLY
